NRG-GI005

Complete

Return to Protocol Table

Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA
Colon Cancer (COBRA)

Principal Investigator

Van Morris, MD

Status

Complete

Date Opened To Accrual

December 16 2019

Date Closed to Accrual

December 01 2022

Disease Site

Gastrointestinal [GI]

Colorectal

Phase

II/III

Developmental Therapeutics

Primary Objective

Phase II - To compare the rate of ctDNA clearance in "ctDNA detected" patients treated with or without adjuvant chemotherapy following resection of stage IIA colon cancer.

Phase III - To compare recurrence-free survival (RFS) in "ctDNA detected" patients treated with or without adjuvant chemotherapy following resection of state IIA colon cancer.

Patient Population

Patients treated with or without adjuvant chemotherapy following resection of stage IIA colon cancer

Target Accrual

1408

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Other

NRG-GI005, the "COBRA" Study Overview by Van Morris, MD

Webinar: "Surgical implications of ctDNA: Is this the future for colon cancer?"

Patient Study Webpage

To learn more about this study, visit the Patient Study Webpage.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.